financetom
Business
financetom
/
Business
/
Diesel brand owner OTB is positive on China and in no rush to IPO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Diesel brand owner OTB is positive on China and in no rush to IPO
Oct 16, 2025 7:26 PM

SHANGHAI (Reuters) -OTB Group, the parent of Italian denim specialist Diesel and owner of luxury brands including Maison Margiela, is positive on the Chinese market and is investing more in it, founder and chairman Renzo Rosso said.

Rosso, in China to mark Diesel's 20 years in that market, said he is continuing to invest in China in a down market, rejigging OTB's retail footprint by closing some stores, but continuing to open in new and better locations.

"I am positive. I think if the market is going like this, it can be an opportunity because we can have a better space available for a better price that wasn't available before," he said. "My vision right now is to invest in the country. I believe in the country; it is so big, so important."

Rosso was speaking to Reuters on Thursday ahead of a dinner for around 100 people with a view of Shanghai's famous skyline.

"This year, we are doing well compared with the market. Everybody is minus, we are a little plus, so we are quite happy," he added.

China's consumer appetite has been in focus for global brands, especially in the high-end and luxury sectors which count on Chinese nationals for around one-third of global purchases.

In recent years, consumer demand in the world's second-largest economy has been dampened by a prolonged property market crisis and concerns about job security and wage growth in an economy buffeted by factors including slowing growth and a trade war with the U.S.

In an indication of how vital China is to luxury, reports from industry bellwether LVMH earlier this week that Chinese demand is improving sparked an $80 billion stock market rally for the sector.

OTB, or Only the Brave, is also home to luxury brand Jil Sander, and as a group reported turnover of 1.8 billion euros ($2.11 billion) in 2024, a fall of 4.4%.

In 2024, OTB postponed plans for a public listing originally slated for this year, saying it would probably delay it until 2026. Rosso remains in no hurry to go public.

"First of all, I don't need the money, I am cash positive," he said. "There's no rush, it can be one year, two years, I don't care. If I feel good, then yes."

($1 = 0.8551 euros)

(Reporting by Casey Hall; Editing by Muralikumar Anantharaman)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Westaim Completes US$79-Million Sale of Remaining Interest in Skyward Specialty Insurance
Westaim Completes US$79-Million Sale of Remaining Interest in Skyward Specialty Insurance
Sep 11, 2024
05:02 PM EDT, 09/10/2024 (MT Newswires) -- Westaim ( WEDXF ) after trade Tuesday said it sold all its remaining 1.91-million shares in Skyward Specialty Insurance Group. The investment-holding company said proceeds, less commissions, were approximately US$79 million. Westaim's ( WEDXF ) remaining investments include significant interests in Arena and the Arena FINCOs. The company's shares closed down $0.04 to...
Abercrombie & Fitch Insider Sold Shares Worth $2,501,264, According to a Recent SEC Filing
Abercrombie & Fitch Insider Sold Shares Worth $2,501,264, According to a Recent SEC Filing
Sep 11, 2024
05:10 PM EDT, 09/10/2024 (MT Newswires) -- Samir Desai, Executive Vice President, Chief Digital & Technology Officer, on September 06, 2024, sold 19,041 shares in Abercrombie & Fitch ( ANF ) for $2,501,264. Following the Form 4 filing with the SEC, Desai has control over a total of 27,985 shares of the company, with 27,985 shares held directly. SEC Filing:...
BridgeBio to stop development of therapy for genetic disorder
BridgeBio to stop development of therapy for genetic disorder
Sep 11, 2024
Sept 10 (Reuters) - BridgeBio Pharma ( BBIO ) said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland. The drugmaker said the results of its early-to-mid stage study testing the therapy did not meet the threshold to warrant additional capital investment. (Reporting by Puyaan Singh; Editing by Shinjini Ganguli)...
Sentinelone Insider Sold Shares Worth $1,140,682, According to a Recent SEC Filing
Sentinelone Insider Sold Shares Worth $1,140,682, According to a Recent SEC Filing
Sep 11, 2024
05:00 PM EDT, 09/10/2024 (MT Newswires) -- Ric Smith, Chief Product & Technology Officer, on September 06, 2024, sold 51,052 shares in Sentinelone ( S ) for $1,140,682. Following the Form 4 filing with the SEC, Smith has control over a total of 585,647 shares of the company, with 585,647 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1583708/000158370824000078/xslF345X05/wk-form4_1726001520.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved